PCOS Has an Official New Name: What the Lancet's May 2026 Announcement Means for Your Fertility.

by Heather Kish | Harvest Health with Heather

On May 12, 2026, a landmark paper published in The Lancet officially announced what researchers, clinicians, and a great many patients have known for years: the name Polycystic Ovary Syndrome was always wrong.

After 14 years of global collaboration, more than 22,000 survey responses from patients and clinicians, and input from 56 patient and professional organizations worldwide, the Global Name Change Consortium announced the formal rename to PMOS: Polyendocrine Metabolic Ovarian Syndrome.

The change affects approximately 170 million women worldwide — roughly 1 in 8.

It is not a rebranding. It is a clinical acknowledgment that the old name directed care toward the wrong thing for nearly a century, and that the consequences of that misdirection have been profound.

As Professor Helena Teede of Monash University, one of the lead researchers, put it: "a name change was the next critical step towards recognition and improvement."

Rachel Morman, Chair of Verity/PCOS UK, said it more plainly: "the new name now leads with hormones and recognizes the metabolic dimension."

If you have been diagnosed with PCOS and have spent years feeling like the explanation never quite explained anything, this is why.

What the Lancet Paper Actually Found

The Lancet paper (PIIS0140-6736(26)00717-8) was the culmination of 14 years of multidisciplinary research and consultation, including surveys from 14,360 people living with the condition and over 22,000 total survey responses from patients and health professionals across 56 organizations.

Among the core findings that drove the rename:

• There is no actual increase in abnormal ovarian cysts in the condition. The defining feature the condition was named after — the cysts — is not a consistent or reliable marker of the underlying syndrome. Many women with classic PCOS have no cysts on ultrasound at all.

  
  

• PCOS affects multiple body systems, not just the reproductive organs. The polyendocrine component of PMOS reflects that this condition involves the endocrine system broadly: insulin, cortisol, thyroid function, and androgen pathways all interact in the condition.

  
  

• Insulin resistance, hormonal imbalance, and inflammation are the core mechanisms. Not ovarian structure.

  
  

• The cardiometabolic consequences are as significant as the reproductive ones. Women with PMOS carry elevated risk for insulin resistance, prediabetes, type 2 diabetes, high cholesterol, and cardiovascular disease — risk factors that standard PCOS management has historically underemphasized.

  
  

• Diagnosis has been chronically delayed because the name led both clinicians and patients to look for the wrong signs. Women without visible cysts on ultrasound were routinely dismissed.

  
  

The Lancet paper also confirmed a 3-year global transition period, with full implementation of PMOS in the 2028 International Guideline update. Which means for the next few years, you will see both names in clinical settings. Both refer to the same condition.

Reference: Global Name Change Consortium. "Renaming Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome." The Lancet, May 13, 2026. doi.org/10.1016/S0140-6736(26)00717-8

Why the Old Name Was Always the Wrong Name

Polycystic Ovary Syndrome was named in 1935 by gynecologists Irving Stein and Michael Leventhal, who described a group of women with enlarged ovaries containing multiple small follicles, irregular periods, and signs of androgen excess. The name described what they could see at the time.

The problem is that what they saw was a consequence, not a cause.

Those small, stalled follicles — the cysts — form because the hormonal environment inside the ovary disrupted normal follicle maturation. That disruption, as decades of research would show, is driven by dysregulated insulin signaling and elevated androgens. Nothing structurally wrong with the ovary caused it. The ovary was responding to a systemic signal.

By naming the condition after its most visible feature, clinical attention anchored to the ovaries and the cysts, while the metabolic system producing the signal those ovaries were responding to went largely unaddressed.

The Rotterdam Criteria, established in 2003, improved diagnostic accuracy by requiring only two of three features: polycystic ovaries on ultrasound, irregular ovulation, or elevated androgens. But the name held. And with it, so did the treatment logic: manage the cycle, induce ovulation, suppress symptoms.

The Lancet paper's finding that there is no actual increase in abnormal cysts in the condition closes the loop on the name. The cysts were never the story. The new name reflects that.

Reference: Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome." Fertility and Sterility, 2004. doi.org/10.1016/j.fertnstert.2003.10.004

What PMOS Actually Is: Polyendocrine, Metabolic, Ovarian

The new name carries real clinical meaning. Each word matters.

Polyendocrine reflects that this is not a single-hormone condition. It involves the interaction of insulin, androgens (testosterone, androstenedione), cortisol, and in many cases thyroid function. The endocrine disruption is systemic.

Metabolic reflects what drives the condition at its root. Insulin resistance is present in approximately 70 to 95 percent of women with PMOS, regardless of body weight. When cells become resistant to insulin's signaling, the body compensates with more insulin. Elevated circulating insulin then amplifies the ovarian signal to produce androgens. Elevated androgens disrupt follicle maturation, ovulation, and progesterone production.

Ovarian acknowledges that the reproductive consequences are real and significant, while no longer centering the ovaries as the origin of the problem. They are the site where the systemic metabolic disruption expresses itself most visibly in the reproductive years.

The fertility implications of this cascade are specific:

• Ovulation is disrupted because elevated androgens interfere with the LH surge required to release a mature egg

• Egg quality is impaired because elevated intraovarian androgens compromise mitochondrial function within the developing egg — mitochondria being responsible for the cellular energy a fertilized egg needs to divide, develop, and implant

• Progesterone in the luteal phase is often insufficient, shortening the implantation window and contributing to early pregnancy loss

• IVF outcomes can be compromised even with high follicle counts, because the eggs are maturing in a metabolically disrupted environment — which is why blastocyst conversion rates and embryo arrest patterns often tell a different story than antral follicle counts alone.

  
  

Reference: Escobar-Morreale HF. "Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment." Nature Reviews Endocrinology, 2018. doi.org/10.1038/nrendo.2018.24

Reference: Dumesic DA et al. "Oocyte environment: follicular fluid and cumulus cells are critical for oocyte health." Fertility and Sterility, 2015. doi.org/10.1016/j.fertnstert.2015.05.022

Why Your Labs Can Look Normal and the Problem Still Be There

One of the most disorienting parts of living with PMOS is having every standard test come back normal while knowing something is wrong. The Lancet findings on delayed diagnosis validate that experience. The name led clinicians to look for the wrong signs. But the testing gap compounds it further.

Standard fertility panels screen for fasting glucose and sometimes HbA1c. These markers identify established diabetes. They do not detect the earlier stage of insulin dysregulation where insulin is already elevated, androgens are already elevated, and the hormonal disruption to the reproductive system is already underway.

A woman can have:

• Fasting glucose of 88 mg/dL (within normal range)

• Fasting insulin of 18 uIU/mL (functionally elevated, driving androgen production)

• HOMA-IR of 3.4 (significant insulin resistance)

  
  

And not a single value will flag as abnormal on a standard lab report.

The markers that reveal what standard testing misses:

• Fasting insulin — drawn fasting, ideally under 8 uIU/mL functionally

• HOMA-IR — calculated from fasting glucose and fasting insulin; under 1.5 is optimal

• Free testosterone alongside total testosterone

• SHBG (sex hormone-binding globulin) — low SHBG means more free testosterone is circulating

• Triglyceride-to-HDL ratio — a validated proxy for insulin resistance

  
  

None of these appears in a standard fertility workup. All are standard clinical laboratory tests.

What the Rename Means for Your Care — Right Now

The Lancet paper projects faster and more accurate diagnoses, reduced delays, more personalized care, and earlier intervention for cardiometabolic complications as outcomes of the rename. That is the 3-year roadmap.

What it means for you right now, while clinical systems are still in transition:

The question worth asking at your next appointment is no longer "is my PCOS being managed?" It is: "What are we doing to address the polyendocrine and metabolic components of this condition, not just my cycle symptoms?"

That framing is harder to answer with a prescription refill. It requires an actual metabolic evaluation.

If your treatment history has been birth control to regulate cycles, Clomid or Letrozole to induce ovulation, or a referral to IVF without any evaluation of your insulin, SHBG, or androgen picture — the metabolic root has not been addressed. The rename does not fix that. But it gives you the language to name what is missing from your care.

Root-cause approaches to PMOS that have documented evidence behind them include:

• Meal composition changes — protein before carbohydrates to reduce postprandial insulin spikes

• Myo-inositol supplementation (2,000 to 4,000 mg daily) — shown in multiple RCTs to improve insulin sensitivity, reduce testosterone, and restore ovulatory frequency

• Resistance training (2 to 3 sessions weekly) — activates insulin-independent glucose uptake in muscle cells

• Nervous system regulation — cortisol and insulin are closely linked; chronic stress compounds insulin resistance

  
  

Reference: Unfer V et al. "Inositols in Polycystic Ovary Syndrome." Expert Review of Molecular Diagnostics, 2023. doi.org/10.1080/14737159.2023.2220699

Explore This Further in The Egg Awakening Directory - The Fertility Hub

My directory covers the metabolic, hormonal, and egg quality dimensions of PMOS in depth. If you want to go further on any piece of what this article covers:

• PCOS has a new name. What does PMOS mean for my care? — Direct Q&A on the rename, what changes clinically, and what to ask your provider

• Could hidden insulin resistance be disrupting my cycle? — The specific markers that reveal insulin resistance before fasting glucose rises

• How does blood sugar affect my eggs and hormones? — How elevated insulin disrupts follicle development and egg quality

• What actually determines egg quality? — Why egg quality reflects the past 90 days of metabolic health

• What does a standard fertility panel completely miss? — The testing blind spots that keep women stuck with "normal" results

  
  

Explore the full directory

FAQ

What does PMOS stand for? Polyendocrine Metabolic Ovarian Syndrome. The rename was officially published in The Lancet on May 13, 2026, following 14 years of global research collaboration and input from over 22,000 patients and health professionals across 56 organizations. The term "polyendocrine" reflects that the condition involves multiple hormonal systems, not just the ovaries. "Metabolic" places insulin resistance and its downstream hormonal effects at the center of the clinical picture.

Does this mean my PCOS diagnosis is now PMOS? Yes, the same condition. There is a 3-year transition period, with full implementation expected in the 2028 International Guideline update. You will see both terms in clinical settings during that period. Both refer to the same underlying condition. What matters most is whether your care is being directed at the metabolic root, regardless of which name appears in your chart.

My ultrasound showed no cysts. Does this rule out PMOS? No — and one of the Lancet paper's key findings is that there is no actual increase in abnormal ovarian cysts in the condition. The cysts are not a defining feature. Under the Rotterdam Criteria, you need only two of three diagnostic markers: polycystic ovaries on ultrasound, irregular ovulation, or elevated androgens. Women without ultrasound findings but with the hormonal and metabolic picture have always qualified for a diagnosis. The rename is intended to reduce the diagnostic weight placed on the visual finding that has been missing in many women who clearly have the condition.

My labs are normal. Can I still have PMOS? Yes. Standard labs screen for established metabolic disease, not for the earlier stage of insulin dysregulation that drives PMOS. Fasting glucose and HbA1c can be entirely normal while fasting insulin is elevated and the androgen cascade is active. The specific markers to request are fasting insulin, HOMA-IR (calculated from both values), SHBG, and free testosterone. These are standard tests that are rarely included in a routine fertility workup.

How quickly can addressing the metabolic root affect my fertility? Research consistently shows measurable improvements in fasting insulin and HOMA-IR within 8 to 12 weeks of targeted metabolic intervention. Cycle regularity tends to improve within one to three cycles after insulin normalizes. Egg quality improvements require approximately 90 days, which is the full follicle development cycle from recruitment to ovulation. A structured 90-day window of metabolic-focused work before a retrieval or natural conception attempt is physiologically meaningful.

Heather Kish is a fertility health coach and creator of The Egg Awakening, a 90-day root-cause fertility coaching program for women navigating unexplained infertility. She conceived via IVF at 44 after four years of her own fertility journey. Learn more at harvesthealthwithheather.com.

This post is for educational purposes and does not constitute medical advice. Please work with a qualified healthcare provider for diagnosis and treatment.